The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value
Dr. Dereck Mush, MD, MBA
Pathway Labs
Cardiovascular AI using routine ECGs to flag possible structural heart disease for further assessment.
What they do
Pathway Labs develops EchoNext, cardiovascular notification software cleared under K260332 on June 8, 2026. It analyzes compatible 12-lead ECGs to support referral and follow-up, not confirm a diagnosis. The company announced an $8.5 million seed and an OpenEvidence distribution partnership on June 23, 2026.
The record
- Vertical
- Cardiovascular
- Sub-segment
- ECG-based risk assessment
- Product type
- Software as a medical device
- Stage
- Seed
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $8.5M raised
Notable investors: AlleyCorp, Breyer Capital.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
Inside EchoNext: The ECG Is Only the Beginning
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
Opportunistic Valvular Screening: How Routine ECG-AI Expands the Structural Heart Pipeline
Dr. Dereck Mush, MD, MBA